ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Biomarker profiles in late-life depression and Alzheimer's disease across and beyond the A/T/N framework: A scoping review.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Depression and Alzheimer's disease (AD) frequently overlap clinically, and depressive symptoms may signal major depressive disorder, a risk factor for AD, or an early manifestation of neurodegeneration. This scoping review mapped biomarker evidence differentiating depression and AD within and beyond the amyloid/tau/neurodegeneration (A/T/N) framework. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines, MEDLINE, Embase, and Scopus were searched for studies published between 2010 and 2025 examining biomarkers in depression and AD. Eligible studies included clinical diagnoses of AD and/or depression and reported biomarker measures. Forty-eight studies met inclusion criteria. Amyloid biomarkers were most consistently associated with clinically diagnosed AD, whereas findings for other biomarkers were more heterogeneous. Neurodegeneration markers, including hippocampal atrophy, were commonly associated with AD, while vascular abnormalities and altered functional connectivity were more frequently linked to depressive symptoms. Overall, AD and depression demonstrated partially distinct but overlapping biomarker profiles, highlighting the need for longitudinal studies using scalable biomarkers to clarify causal and temporal relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.